The cooling towers of Unit 2 at Three Mile Island Nuclear Generating Station, closed since the accident in 1979.
The Three Mile Island accident in 1979 was the most-studied nuclear reactor event in the U.S. There is a plethora of research about the accident available to the general public, including the president-appointed Kemeny Commission report and the Nuclear Regulatory Commission’s Rogovin inquiry report (split into volume one, and volume two, parts one, two, and three), which are the two detailed government-sponsored investigations into the accident. There are also thousands of documents in the NRC’s ADAMS database available to the public, an excellent overview by NRC historian Samuel Walker Three Mile Island: A Nuclear Crisis in Historical Perspective, as well as the Nuclear News special report from April 1979, and articles written by ANS members like William Burchill about the accident and the many changes it forced on the industry. If the producers of Meltdown: Three Mile Island—available on Netflix—had read any of those documents instead of relying mostly on input from antinuclear activists, their “documentary” might have been presented with at least some sense of balance and credibility.
Instead, similar to a recent Science Channel documentary on the Three Mile Island accident, Meltdown focuses on drama instead of science. This four-part miniseries does not attempt to provide a balanced set of facts from the technical community and instead relies heavily on nonexpert opinions and anecdotal statements to tell a story that easily falls apart under even the faintest scrutiny.
Nuclear News reached out to multiple ANS members who were involved with either the accident response or the clean up to help provide a critical look at some of the more egregious statements made in the documentary.
The DOE and a contractor recently succeeded in disposing of Oak Ridge’s low-activity U-233, but not before recovering Th-229 from the material.
A vial containing Th-299 extracted from uranyl nitrate.
This past October, the Department of Energy’s Oak Ridge Office of Environmental Management (OREM) and its contractor Isotek successfully completed processing and disposing the low-dose inventory of uranium-233 stored at Oak Ridge National Laboratory (ORNL), ending a two-year effort that has eliminated a portion of the site’s legacy nuclear material and provided rare nuclear isotopes for next-generation cancer treatment research.
IAEA director general Rafael Mariano Grossi (left) and WHO director general Tedros Adhanom Ghebreyesus. (Photo: IAEA)
The International Atomic Energy Agency has launched the Rays of Hope program to tackle a severe shortage of cancer care capacity in poorer countries. The program’s initial focus will be on Africa, where people often die from the disease because of the lack of access to potentially life-saving nuclear medicine and radiotherapy, according to the IAEA.
A video on the program is available on YouTube.
SHINE’s Mo-99 production facility under construction in Janesville, Wis. (Photo: SHINE)
SHINE Europe, a nascent subsidiary of Wisconsin-based SHINE Technologies, announced Wednesday that it has secured funding to begin designing an advanced medical isotopes facility in Veendam, the Netherlands. The new facility will use the same fusion-based neutron generator system SHINE is employing at its Janesville, Wis., facility to produce medical isotopes, including molybdenum-99, which is used in diagnostic imaging.
The cover of the August 1969 issue of Nuclear News (left), an image of Brunhilde, the dog that had the first nuclear-powered pacemaker in the U.S. (center) and the cover of the December 1970 Nuclear News (right).
In this first installment of a #ThrowbackThursday post, Nuclear News provides a review of radioisotope-powered pacemakers in response to an article in The Wall Street Journal. The article, published earlier this week, looks at the issue of disposing of nuclear-powered pacemakers, although considering how few are still in use today, it seems like this is really much ado about nothing.
Darlington nuclear power plant. (Photo: OPG)
The Canadian Nuclear Safety Commission (CNSC) has amended Ontario Power Generation’s (OPG) operating license for its Darlington nuclear power station near Clarington, Ontario, allowing the company to produce the medical radioisotope molybdenum-99 using Darlington’s Unit 2 CANDU reactor. OPG subsidiary Laurentis Energy Partners, in conjunction with BWXT Medical, is leading the program to produce Mo-99 at Darlington.
SHINE Technologies’ headquarters building in Janesville, Wis. (Photo: SHINE)
The Department of Energy’s National Nuclear Security Administration has issued a cooperative agreement worth $35 million to SHINE Technologies, based in Janesville, Wis., to support the commercial production of molybdenum-99, a critical isotope used in more than 40,000 medical procedures in the United States each day, including the diagnosis of heart disease and cancer.
A PET imaging machine. (Photo: Wikimedia Commons)
ARTMS, a Canadian producer of medical isotopes, announced that it has registered the cyclotron production of gallium-68 with the government of Canada, filing a Type 1 Master File with the Health Products & Food Branch of Health Canada. The Ga-68 radioisotope is used in nuclear medicine diagnostic procedures utilizing positron emission tomography (PET) imaging.
Chemist Kevin Gaddis has adapted components of a high-pressure ion chromatography system to withstand the extreme conditions of a hot cell. (Photo: ORNL/Carlos Jones)
An Oak Ridge National Laboratory researcher has built a device that can speed up the separation of the medical radioisotope actinium-225 from irradiated thorium targets and withstand the high-radiation environment of a hot cell. In July, ORNL announced that Kevin Gaddis, a chemistry technician at the lab, had built and tested a prototype and was working to secure a patent for a device that cut separations time by 75 percent.